MRNA vs APP Stock Comparison: Price, Growth & Valuation (2026)
Use MEXC Stock Compare for a detailed MRNA vs APP analysis. Compare MRNA and APP across price performance, growth, valuation, profitability and risk, based on market data and the latest reported financials.
MRNA vs APP Stock Comparison Summary
MRNA reported year-over-year revenue growth of -27.6%, compared with 60.6% for APP. Their P/E ratios are -- and 23.9x, dividend yields are 0.00% and 0.00%, and 30-day volatility levels are 306.1% and 44.9%, respectively. These metrics highlight key differences in growth, valuation, dividend income and market risk. Overall APP leads across more of the selected comparison metrics.
Risk Disclaimer: MEXC Stock Compare provides information and comparisons on actual U.S.-listed stocks for reference only. Data may be delayed or inaccurate, does not constitute investment advice, and past performance does not guarantee future results.
MRNA vs APP Stock Return Comparison (1W)
Compare the cumulative total returns of Moderna, Inc. (MRNA) and Applovin Corporation (APP) over the selected 1W period. Data as of 2026-09-24 12:00:00.
MRNA vs APP Key Equity Metrics Comparison Summary
Moderna, Inc. (MRNA) has a market capitalization of $70.41B and operates in the Health Care sector, with its main business classified under Biotechnology. Its latest quarterly revenue changed -27.6% year over year.
Applovin Corporation (APP) has a market capitalization of $94.84B and operates in the Information Technology sector, with its main business classified under Application Software. Its latest quarterly revenue changed +60.6% year over year.
MRNA vs APP Key Stock Indicators
| Comparison Metric | MRNA | APP | Comparison results |
Stock Price & Returns Latest delayed stock price with 1-day, 1-month and year-to-date returns. | $176.351D: +1.7%1M: +24.5%1Y: +581.4% | $311.501D: +0.3%1M: +2.0%1Y: -51.5% | MRNAWin |
Market Capitalization Total market value of the company's outstanding shares. | $70.41B | $94.84B | APPWin |
Sector & Industry The company's market sector and primary industry classification. | Health Care / Biotechnology | Information Technology / Application Software | -- |
| Based on delayed market data, MRNA is trading at $176.35, compared with $311.50 for APP. Their market capitalizations are $70.41B and $94.84B, respectively. MRNA operates in the Health Care sector, while APP belongs to Information Technology. | |||
| MRNA vs APP Growth & Profitability | |||
Revenue Growth (YoY) Year-over-year change in revenue. | -27.6% | +60.6% | APPWin |
EPS Growth (YoY) Year-over-year change in earnings per share. | -4.6% | +84.8% | APPWin |
ROIC Return generated from invested capital. | -39.4% | 132.2% | APPWin |
Gross Margin / Operating Margin Profitability before and after operating expenses. | 23.4% / -149.0% | 88.5% / 77.4% | APPWin |
| On growth, MRNA posted revenue growth of -27.6% and TTM EPS growth of -4.6%. APP, by comparison, posted revenue growth of +60.6% and TTM EPS growth of +84.8%.On profitability, MRNA recorded a gross margin of 23.4%, an operating margin of -149.0%, and ROIC of -39.4%. For APP, the corresponding figures were 88.5%, 77.4%, and 132.2%.Overall, APP shows stronger overall growth and profitability. | |||
| MRNA vs APP Valuation & Balance Sheet | |||
Free Cash Flow Yield Free cash flow as a percentage of market capitalization. | -- | 4.3% | -- |
Net Debt / EBITDA Net debt relative to EBITDA; a negative value indicates net cash. | 0.6x | 0.2x | APPWin |
Dividend Yield / Payout Ratio Dividend returns relative to share price and the share of earnings paid as dividends. | 0.00% / 0.0% | 0.00% / 0.0% | -- |
| The two stocks offer a similar free cash flow yield, indicating comparable valuations. APP has the stronger balance sheet, while the two stocks offer the same dividend yield. Overall, the two stocks differ mainly in valuation, financial strength and dividend income. | |||
| MRNA vs APP Returns & Risk | |||
Total Return (Dividend-Adjusted) Cumulative return over 1, 5 and 10 years, including dividends. | 1Y: +581.4%5Y: -59.0%10Y: +848.1% | 1Y: -51.5%5Y: +292.0%10Y: +377.8% | MRNAWin |
30-Day Realized Volatility Annualized volatility based on the past 30 days of daily returns. | 306.1% | 44.9% | APPWin |
Beta (5Y vs S&P 500) Sensitivity to market movements; above 1 indicates greater market volatility. | 1.36 | 2.20 | MRNAWin |
| MRNA has delivered stronger long-term returns, but the risk indicators show mixed results. | |||
MRNA vs APP Valuation & Dividend Metrics
Review MRNA compared with APP across valuation, cash flow and dividend metrics, including P/E, forward P/E, free cash flow yield and dividend yield. These figures are provided for reference only and do not represent a fair-value estimate, price target or investment recommendation.
| Metric | MRNA | APP | Comparison results |
|---|---|---|---|
Market Cap | $70.41B | $94.84B | APPWin |
P/E (TTM) | -- | 23.9x | -- |
P/S | 32.6x | 15.4x | APPWin |
EV/EBITDA | -23.3x | 19.5x | MRNAWin |
Dividend Yield | 0.00% | 0.00% | -- |
MRNA vs APP Profitability Over Time
Compare MRNA and APP across gross margin and operating margin trends over time to understand how each company's profitability has changed. Based on reported financial data only; not a forecast or investment advice.
| TTM | 3Y Avg | 5Y Avg | 10Y Avg | |
|---|---|---|---|---|
| MRNA | 55.3% | 47.2% | 59.9% | 74.8% |
| APP | 87.9% | 84.1% | 74.5% | 74.5% |
Technical & Fundamental Stock Analysis
RSI (14, daily)
MRNA 67.88 • APP 43.20
Measures short-term price momentum and helps identify possible overbought or oversold conditions.
50/200-DMA Position
MRNA 50D Above / 200D Above • APP 50D Below / 200D Below
Shows whether the stock is trading above or below its medium- and long-term trend lines.
R&D % of Revenue
MRNA 129.1% • APP 4.7%
Shows how much of revenue is invested in research and development.
Share Count Trend (3Y)
MRNA Increased • APP Decreased
Shows whether the company's share count has increased or decreased over the past three years.
Company Profiles
Moderna, Inc.
Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Applovin Corporation
Application Software
AppLovin is a vertically integrated advertising technology company that serves as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange that facilitates transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is Axon 2, an ad optimizer within the DSP that lets advertisers place ads based on specified return thresholds.
Trade MRNA & APP Stock Futures on MEXC
Trade USDT-margined Stock Futures referencing MRNA and APP on MEXC, with 24/7 access and leverage of up to 10x. These products are derivatives, do not represent ownership of the underlying shares and involve a significant risk of loss.
Everything You Need to Know About MRNA vs APP Stocks
What is MEXC Stock Compare?
MEXC Stock Compare is a side-by-side US stock comparison tool. It helps users compare two companies across stock price performance, market cap, valuation, growth, profitability, balance-sheet strength, dividends and risk. The results are provided for research purposes only and do not constitute investment advice.
Which metrics should I use to evaluate a company's growth?
Start with revenue growth to see how quickly the business is expanding, then review EPS growth to determine whether that growth is translating into higher earnings per share. Gross margin, operating margin and ROIC help assess the quality of that growth by showing profitability and capital efficiency. A company with fast revenue growth but declining margins may be expanding without improving its earnings quality.
How do MRNA and APP compare in growth and profitability?
In the latest reported period, MRNA recorded revenue growth of -27.6% and TTM EPS growth of -4.6%, compared with +60.6% and +84.8% for APP. APP leads on both growth and profitability. This comparison is based on reported financial metrics and does not predict future performance.
What is the difference between P/E (TTM) and Forward P/E?
P/E (TTM) compares the current share price with actual earnings reported over the past 12 months. Forward P/E uses estimated earnings for the next 12 months, so it reflects market expectations but depends on forecasts that may change. Both ratios should be considered alongside growth, profitability and industry peers.
How do the risk profiles of MRNA and APP compare?
MRNA has a 30-day realized volatility of 306.1% and a five-year Beta of 1.36, compared with 44.9% and 2.20 for APP. The risk indicators show mixed results. These indicators describe historical price movements and market sensitivity, but they do not cover every source of investment risk.
What do dividend yield and payout ratio indicate?
Dividend yield shows the annual dividend relative to the current share price, while the payout ratio shows how much of a company's earnings is distributed as dividends. A higher yield may provide more income, but it can also rise because the share price has fallen. Dividend sustainability should therefore be considered together with earnings, cash flow and the payout ratio.
How should I compare a high-growth stock with a lower-valued stock?
A high-growth stock may trade at a higher valuation if investors expect its revenue and earnings to continue expanding. A lower-valued stock may offer a more conservative entry point, but the lower valuation could also reflect slower growth or higher business risk. Growth, valuation, profitability, cash flow and risk should therefore be considered together.
Which is the better stock, MRNA or APP?
There is no single answer for every investor. Growth-focused investors may place greater weight on revenue growth, EPS growth and ROIC, while income-focused investors may prioritize dividend yield and payout sustainability. Investors with lower risk tolerance may focus more on volatility, Beta and balance-sheet strength. MEXC Stock Compare presents the relevant metrics but does not provide a buy or sell recommendation.
Can I trade MRNA and APP as RealStocks on MEXC?
Eligible users can trade MRNA and APP as real US stocks through MEXC RealStocks if both stocks are currently supported. Users must first open and verify a RealStocks account with MEXC's partner licensed broker. RealStocks represents ownership of actual shares rather than tokenized stock exposure. Availability may vary by stock and region, so users should check the corresponding RealStocks trading page before placing an order.
Disclaimer
The stock prices, financial metrics, comparison results and related information displayed on this page are sourced from third-party providers and are provided for informational and educational purposes only. Data may be delayed, incomplete or inaccurate, and MEXC does not guarantee its accuracy, completeness or timeliness. The comparisons and automated summaries do not constitute financial, investment, legal or tax advice, nor a recommendation to buy, sell or hold any security or financial product. Past performance is not indicative of future results. Users should independently verify the information and assess their own objectives, financial circumstances and risk tolerance before making any decision. Where MEXC stock futures or other derivative products are referenced, such products do not represent ownership of the underlying shares and may involve leverage and a substantial risk of loss. Product availability is subject to applicable laws and regional restrictions.